Stay tuned for our monthly news!

Stay informed

No, thanks

asd

Article19 Nov 20269 min read

How to Get a CE Mark for a Medical Device After FDA Clearance in 2027

How to get a CE mark for a medical device the FDA has cleared: the 510(k) does not transfer, its test data and your quality system partly do, and the order of six steps and the speed of your answers decide how long European revenue waits.

Last updated: November 2026

In brief

  • No transfer. A 510(k) does not carry over: to get a CE mark for a medical device in class IIa, IIb or III, Regulation (EU) 2017/745 (MDR) requires a certificate from an EU notified body.
  • The clock. Counted from the first day of preparation, excluding any clinical investigation, a certificate takes 12 to 32 months on the quality-system route and 19 to 38 on the product route (CW1 Group calculation from two Commission surveys).
  • The bill. Manufacturers reported median direct costs of €50,000 (about $54,800) for an initial quality-system certificate and €100,000 (about $109,700) per product certificate (data through October 2025).
  • The order. Few applications are refused, but of the 524 refusal reasons notified bodies gave by February 2026, 254 concerned scope, classification or procedure (CW1 Group count).

Does FDA clearance count toward a CE mark?

Clearance by the U.S. Food and Drug Administration (FDA) counts as evidence and nothing more: under the MDR, devices in classes IIa, IIb and III need an EU notified body's certificate to carry the CE mark (Article 52). The class comes from the 22 rules of the MDR's Annex VIII, and the FDA's three classes do not carry over: Rule 8 puts surgical meshes, total or partial joint replacements and implants that touch the spinal column in class III, except for components such as screws and plates.

Devices certified under the MDR's predecessor directives have until the end of 2027 or 2028 to transition if they met 2024 deadlines and other conditions (Regulation (EU) 2023/607); a device arriving from the United States in 2027 has no such bridge.

The quality system travels best. Since February 2, 2026, the FDA's Quality Management System Regulation (QMSR) has incorporated ISO 13485:2016 by reference, yet a notified body will still audit the system against the MDR's own list of 13 aspects (Article 10(9)).

The evidence travels in part. Test reports carry over, though the EU file requires complete protocols and data analysis; clinical data are the bigger gap. By the FDA's own account, only a small percentage of 510(k)s require them, while the MDR requires clinical data for every device, barring justified exceptions. A U.S. study, such as an investigational device exemption (IDE) study, counts as a clinical investigation, weighed by whether it met the MDR's rules (Article 61(3)). The predicate stays behind: substantial equivalence allows different technological characteristics that raise no different questions of safety and effectiveness, while the MDR asks for similar technical, biological and clinical characteristics and access to the other device's data (Annex XIV).

Why do FDA-cleared devices stall on the way to a CE mark?

They stall twice: before the notified-body contract, when the steps come in the wrong order, and after it, in rounds of questions. Each European decision narrows the next: the class and, for an implant or a class III device, the MDR's exemption lists set the route and the depth of evidence, and the device type and route determine which notified bodies may take the file.

The notified bodies' figures, which cover all applicants, show where the order fails. Refusals are few: 989 of the 31,902 MDR applications submitted by February 28, 2026, in a survey for the European Commission. But of the 524 refusal reasons it tallied separately, sometimes several per application, 254, or 48% by CW1 Group's count, concerned the body's scope, the device's qualification or class, or the procedure, all settled before the file is written. Another 131 cited incomplete applications, and only 14 of the 52 bodies said that most submissions they receive are complete.

Why notified bodies refused MDR applications

Refusal reasons recorded up to February 28, 2026, in the survey's detailed data: 524 in all, and one application can have several. In its smaller dataset, 989 of the 31,902 MDR applications submitted had been refused.

Decided before the file is written: scope, class, procedureOther reasons
Outside the body's designation156 · 30%
Incomplete application131 · 25%
Other109 · 21%
Wrong qualification or classification of the device85 · 16%
Insufficient notified-body resources30 · 6%
Wrong conformity assessment procedure13 · 2%
Source: GÖG, Areté and Civic Consulting for the European Commission, notified-body survey on certifications and applications, 52 bodies designated under the MDR, data through February 28, 2026, slides 16 and 28. Shares of the 524 reasons calculated by CW1 Group from the counts in the survey.

The law sets part of the order. A manufacturer registers in EUDAMED, the European database on medical devices, and receives the single registration number (SRN) it needs to apply to a notified body (Article 31). For a company outside the EU, EUDAMED's guide adds a step: the registration names an EU Authorized Representative, which holds the company's mandate and verifies the request before the competent authority in the representative's country validates it. A missing mandate blocks the SRN and, with it, the application. Starting February 25, 2027, a notified body may quote only once it knows the representative and the device's purpose, characteristics and class, a rule meant to prevent refusals for incompleteness or scope (Implementing Regulation (EU) 2026/977, Article 1 and recital 5).

What do the two MDR routes cost in months and money?

Counted from the first day of preparation, an MDR certificate takes 12 to 32 months on the quality-system route and 19 to 38 months when a product certificate is added. That is CW1 Group's calculation from the Commission's surveys, using the two time ranges notified bodies cite most for each route, excluding any clinical investigation.

Two routes to an MDR certificate, in months and eurosThe class, and for class IIb implants whether they are on the Article 52(4) list, set the route (MDR Article 52). Months as notified bodies and manufacturers reported them; costs are manufacturers' medians, with averages in parentheses, per certificate or, for the clinical evaluation, per device, data through October 2025.
Phase or costQuality-system routeProduct route (quality system and product)
DevicesClass IIa; class IIb, including the implants on the list in Article 52(4), extended in July 2026 to dental implants, bone substitutes, nails, anchors, catheters and othersClass III, including surgical meshes, joint replacements and implants that touch the spinal column, except components such as screws and plates (Rule 8); class IIb implants not on that list
What the body reviewsThe quality system, and the technical documentation of at least one representative device per category or generic device groupThe quality system, and the technical documentation of every device, each with its own certificate
Clinical investigationThe default only for the implants on this route, unless the Article 61(6)(b) list or a full-access contract applies; otherwise needed where existing clinical data fall shortThe default (Article 61(4)), unless the Article 61(6)(b) list or a full-access contract applies; it runs before the application
Preparing the application6 to 12 months for 44% of manufacturers6 to 12 months for 44% of manufacturers
Application to written agreementUnder 2 months for 65% of files, according to the bodies; over 3 months for 42% of manufacturersUnder 2 months for 65% of files, according to the bodies; over 3 months for 42% of manufacturers
Written agreement to certificate13 to 18 months for 62% of 47 notified bodies and 6 to 12 for 30%; more than 18 months for about 45% of 102 manufacturers13 to 18 months for 51% of 39 notified bodies and 19 to 24 for 31%; more than 19 months for 54% of 108 manufacturers
From the first day of preparation, excluding any clinical investigation (CW1 Group calculation)12 to 32 months; 25 or more for manufacturers reporting more than 18 months19 to 38 months; 25 or more for manufacturers reporting more than 19 months
Notified-body fees per initial certificate€32,500 (€56,872)€32,500 for the quality system, plus €50,000 (€83,782) per product certificate
Direct cost per initial certificate€50,000 (€88,867)€50,000, plus €100,000 (€194,785) per product certificate
Writing the clinical evaluation, per device€20,000 (€32,774) in IIa; €40,000 (€50,697) in IIb€50,000 (€77,446) in III; €28,500 (€75,007) for IIb implants
Maintenance per certificate, each year€30,000 (€40,694)€30,000 (€46,264) per product certificate, on top of the quality system's
One device, excluding any clinical investigation: certificates, clinical evaluation and a year of maintenance (CW1 Group sum)€100,000 to €120,000 at the medians, about $109,700 to $131,600; €162,335 to €180,258 at the averages€260,000 at the medians for class III, about $285,200; €448,056 at the averages
Sources: notified-body survey for the European Commission, data through February 28, 2026; third manufacturers' survey of the same study, data through October 31, 2025, whose respondents were 81% EU-based (13 of 213 from the United States) and mostly transitioning devices already on the market (111 of the 136 with written agreements held them for legacy devices); MDR, Articles 52 and 61 and Annex VIII, with the lists in Articles 52(4) and 61(6)(b) as replaced by Delegated Regulations (EU) 2026/1359 and 2026/1451. Months add the low and high ends of each phase, using the two ranges most bodies cite: 6 + 0 + 6 = 12 and 12 + 2 + 18 = 32; 6 + 0 + 13 = 19 and 12 + 2 + 24 = 38; for manufacturers reporting more than 18 or 19 months, 6 + 0 + 19 = 25. The surveys give times and certificate costs without a split by class, and do not say what the direct costs include; a certificate's cost may already include part of the clinical evaluation. In MedTech Europe's 2024 survey of a different sample, personnel made up 90% of manufacturers' first-year certification costs and notified-body fees 7%. Dollars at the ECB reference rate of $1.0968 per euro on November 18, 2026, rounded.

Going by the bodies' answers, a certificate within 24 months of starting is mid-range on the quality-system route and fast on the product route, where the low end leaves five months of slack. Manufacturers report longer waits: about 45% of 102 took more than 18 months from contract to a quality-system certificate, and 54% of 108 more than 19 on the product route; with six months of preparation, either means 25 months or more.

If preparation starts in January 2027

Months from the first day of preparation to an MDR certificate, excluding any clinical investigation, and the dates they imply (CW1 Group calculation, for illustration). Dashed line: 24 months.

Start: January 2027Jan 2027Jan 2028Jan 2029May 2030
Quality-system route, notified bodies' two most cited ranges12 to 32 months: January 2028 to September 2029
Product route, notified bodies' two most cited ranges19 to 38 months: August 2028 to March 2030
Manufacturers reporting more than 18 or 19 months after the contract25 months or more: February 2029 or later
Calculation as in the routes table above, from the notified-body survey for the European Commission (data through February 28, 2026) and the third manufacturers' survey (data through October 31, 2025). The survey ranges predate the caps on notified-body time for agreements signed on or after February 25, 2027. Sales follow the certificate once the device is registered in EUDAMED and labeled for each market.

For agreements signed on or after February 25, 2027, Implementing Regulation (EU) 2026/977 caps the notified body's own time at 170 days from a complete application on the Annex IX route: 30 days to the contract, an audit of up to 120 days and a documentation review of up to 90 in parallel, if the audit program allows, then 20 days to decide. The total assumes the default start date, the day after signature. That cap alone is more than twice the FDA's own average time on a 510(k), 75.6 days for those accepted in fiscal 2025, in its August 2026 performance report. And the European clock stops while the company answers questions, normally up to four times in each review, so the caps guarantee no certificate date, and no survey has tested them yet.

Costs come before any European revenue. The median notified-body fees manufacturers reported for an initial quality-system certificate, €32,500 (about $35,600), are already above the FDA's fiscal 2027 fee for a 510(k), $28,653, or $7,163 for a small business, and each certificate then costs a median €30,000 a year to maintain.

How to get a CE mark for a medical device, step by step

A U.S. company gets there in six steps, in this order, and can take the first on its own.

  1. Classify under Annex VIII. Write down the rule, the class, the route it implies and whether Article 61(4) makes a clinical investigation the default. Under Rule 11, software that informs diagnostic or therapeutic decisions is at least class IIa, and IIb or III when those decisions could lead to serious deterioration of health, surgery, irreversible harm or death.
  2. Sign the Authorized Representative's mandate. Appoint a single EU Authorized Representative for the device group (Article 11) and name it in your EUDAMED registration. The representative must verify that your technical documentation and declaration of conformity exist and becomes jointly and severally liable with you for defective devices if you breach your obligations under Article 10.
  3. Shortlist notified bodies, then ask for quotations. In the Commission's NANDO database, keep only bodies designated for your device's codes under Implementing Regulation (EU) 2017/2185 (MDA or MDN for the device type, MDS and MDT for specific characteristics and technologies). In February 2026, 13 of the 52 had issued no certificate on the product route, so ask each how many devices like yours it has certified, and ask for a structured dialogue before applying. Starting February 25, 2027, the quotation must estimate timelines and costs, including typical surveillance and unannounced audits; agree on the start date, by default the day after signature. Apply to one body per procedure: you must declare any application withdrawn or refused elsewhere (Article 53).
  4. Choose the clinical evidence route. Test the predicate against the three groups of characteristics in Annex XIV. If it belongs to another company and your device is implantable or class III, equivalence spares you a clinical investigation only under a contract giving full, ongoing access to its technical documentation, and only if that device's clinical evaluation met MDR requirements (Article 61(5)); types on the Article 61(6)(b) list, extended in July 2026 to dental implants, bone substitutes, pacemaker leads and others, are exempt when their clinical data suffice and any common specification is met. For other devices, sufficient access to the other device's data replaces the contract, and a new investigation follows only where existing clinical data fall short (MDCG 2023-7).
  5. Close the quality-system gaps. Check the system against the 13 aspects of Article 10(9), including post-market clinical follow-up, UDI and vigilance.
  6. Complete the file, apply and manage the review. Submit only an application the body can call complete. Once the contract is signed, name one owner for the body's questions and set a deadline for each reply, since the European clock waits for your answers. Meanwhile, translate labels and instructions into each market's language (German in Germany and French in France for lay users) and line up the EU importer, which must check the CE mark, the representative and the UDI (Article 13), so that EUDAMED registration and the first shipment follow the certificate without delay.
From FDA clearance to CE mark: what carries over at each stepIn the order of the six steps. Owner: who is responsible for the step under the MDR. Typical blocker: the snag to plan for; shares are of the 524 refusal reasons in the Commission's survey.
StepWhat your FDA work already coversWhat the EU addsOwnerTypical blocker
1. MDR classificationThe device description and intended use; the FDA class, one of three, does not carry overFour classes set by 22 rules (Annex VIII); the class and, for implants and class III devices, the lists in Articles 52(4) and 61(6)(b) fix the route and whether a clinical investigation is the defaultManufacturerA wrong qualification or classification: 16% of refusal reasons
2. EU Authorized Representative and EUDAMEDAnnual FDA establishment registration; a UDI from GS1, HIBCC or ICCBBA, which the EU also designatesA sole representative under a written mandate, jointly and severally liable if you breach your obligations, with its own person responsible for regulatory compliance, separate from yours; actor registration and an SRN before applying; a Basic UDI-DI, assigned before applying for class III and for class IIb implants not on the Article 52(4) list, and device registrationAuthorized Representative and manufacturerNo signed mandate: no SRN, so no application
3. Notified body selectionNo direct counterpart; 13 of the 15 MDSAP auditing organizations are EU notified bodies, according to a survey MedTech Europe and COCIR cited in February 2025A body designated for the device's codes (MDA, MDN, MDS, MDT); one application per procedure; starting February 25, 2027, quotations with costs and timelines, and notice of any increase above 10%Manufacturer chooses; the notified body acceptsAn application outside the body's designation: 30% of refusal reasons
4. Clinical evaluationBench and any clinical data; IDE study results, assessed as clinical investigationsA clinical evaluation report based on clinical data (Article 61, Annex XIV); equivalence on technical, biological and clinical grounds with access to the data; a post-market clinical follow-up planManufacturer; the notified body assessesAnother company's predicate: for implants and class III, a clinical investigation unless a full-access contract or the Article 61(6)(b) list applies
5. QMS audit (QMSR vs. ISO 13485)The QMSR has incorporated ISO 13485:2016 since February 2, 2026The 13 aspects of Article 10(9); a person responsible for regulatory compliance (Article 15), within the company unless it is a micro or small enterprise; an initial audit, surveillance at least every 12 months and an unannounced audit at least once every five yearsManufacturer; the notified body auditsCounting on FDA inspections or MDSAP reports: the EU is only an MDSAP observer
6. Technical documentationTest reports: engineering performance, sterility, EMC, software validation, biocompatibilityThe structure of Annexes II and III, with complete protocols and data analysis; a post-market surveillance plan; labels and instructions in each market's languageManufacturer; the notified body assessesAn incomplete application: 25% of refusal reasons
Sources: Regulation (EU) 2017/745, Articles 2, 10, 11, 15, 27, 29, 31, 42, 51 to 53 and 61, Annexes II, III, VIII, IX and XIV, with Articles 52(4) and 61(6)(b) as amended by Delegated Regulations (EU) 2026/1359 and 2026/1451; Implementing Regulation (EU) 2017/2185; Implementing Regulation (EU) 2026/977, Articles 1, 8 and 9; the EUDAMED guide for non-EU manufacturers; MDCG 2019-07 Rev.1; notified-body survey for the European Commission, data through February 28, 2026; FDA pages on classification, the 510(k), IDE, the QMSR, MDSAP, registration and UDI issuing agencies; the Commission's UDI page; MedTech Europe and COCIR, February 2025.

The Commission's proposal of December 16, 2025, to revise the MDR would drop the full-access contract for equivalence and the five-year limit on certificates, but in November 2026 it still awaited a committee decision in the European Parliament: plans for 2027 rest on the rules in force.

How does CW1 Group work with medical device companies?

CW1 Group is a team of strategy and finance consultants who work with physicians, and it has companies in Gothenburg, Frankfurt and Covilhã. With medical device companies, it carries out the initial assessment, designs the strategy, prepares the path and does the first regulatory and financial work, and then the company continues on its own. CW1 Group does not issue certificates, which is the notified body's task, and does not act as an Authorized Representative.

Frequently asked questions

How do I get a CE mark if my device already has FDA 510(k) clearance?

Through an MDR conformity assessment, with an EU notified body for classes IIa, IIb and III, since the 510(k) does not transfer. Its test reports, your quality system and any clinical study results are your starting point.

What are the steps to CE mark a medical device under the EU MDR?

Six, in order: classify under Annex VIII; sign an EU Authorized Representative's mandate and obtain an SRN; shortlist notified bodies and ask for quotations; choose the clinical evidence route; close the quality-system gaps; then complete the file, apply and manage the review while preparing the launch.

Which parts of my FDA submission can I reuse for CE marking?

Most of the test evidence and the quality system: test reports with complete protocols, a QMSR quality system built on ISO 13485:2016, and U.S. clinical study results, assessed as clinical investigations. The FDA class and the predicate do not carry over.

How long does CE marking take after FDA clearance?

In February 2026, 82% of 39 notified bodies cited 13 to 24 months from the written agreement to a new certificate on the product route. From the first day of preparation and excluding any clinical investigation, CW1 Group's calculation gives 19 to 38 months on that route and 12 to 32 on the quality-system route.

Does an MDSAP audit replace the notified body's audit?

No. The European Union is only an official observer in the Medical Device Single Audit Program, and in February 2025 MedTech Europe and COCIR were still asking for MDSAP certificates to count toward CE marking. An MDSAP auditing organization that is also a notified body may combine the two audits.

More insights

We use cookies to give you the best possible experience, and while some are essential, others help us understand how you use the site, so we can improve it. Click “Accept all cookies” to proceed as specified, “Decline optional cookies” to accept only essential cookies, or click “Manage my preferences” to choose what cookie types you will accept. Cookie Policy.

© CW1 Inc, All rights reserved
CW1 Group